Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pioglitazone

- PMLiVE

Alzheon says data backs potential of Alzheimer’s candidate

US biotech points to new analysis of phase III results for tramiprosate

- PMLiVE

Woodford investment pushes Dementia Discovery Fund to £100m

Fund aims to back 40 projects over its 15-year term

- PMLiVE

Takeda’s gamble on Ariad pays off with Alunbrig approval

ALK-inhibitor will treat NSCLC patients as second-line therapy

Online therapy for dementia carers to be studied

UK researchers will assess computerised Cognitive Behaviour Therapy

Holding on to hope for Alzheimer’s advances

Despite another late-stage failure, now is not the time to give up on the disease

Takeda pilots Apple Watch depression app

Partners with Cognition Kit on patient monitoring wearable

- PMLiVE

TiGenix cell therapy for Crohn’s fistulas shows long-term benefit

Phase III data for the Takeda-partnered drug raises hopes for upcoming EU approval

- PMLiVE

Takeda UK & Ireland appoints market access director

Peter Wheatley Price brings experience from GSK, Janssen and Boehringer Ingelheim

- PMLiVE

Takeda agrees $5.2bn deal to buy Ariad

Acquires cancer firm in the first big pharma M&A deal of 2017

- PMLiVE

Valeant’s proposed sale of Salix to Takeda ‘in jeopardy’

Canadian firm now intends to grow Salix salesforce to build Xifaxan and Relistor brands

dengue fever mosquito

Takeda plans German plant to support dengue vaccine roll-out

Will invest more than €100m in the Singen manufacturing facility

- PMLiVE

Takeda gets EU green light for oral myeloma drug

Ninlaro first oral proteasome inhibitor to be registered in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links